Impact of Weight Change in Adults with Type 2 Diabetes Mellitus: A Literature Review and Critical Analysis

References

• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928. doi:10.2337/dci18-0007
   PubMed Web of Science ®Google Scholar
• Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41(5):963–970. doi:10.2337/dc17-1962
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation (IDF). IDF Diabetes Atlas, 8th edition. 2017. Available at: http://www.diabetesatlas.org/. Accessed June 8, 2020.
   Google Scholar
• Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017. Available at: https://www.cdc.gov/features/diabetes-statistic-report/index.html. Accessed June 8, 2020.
   Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.
   PubMed Web of Science ®Google Scholar
• Choy S, Kjellsson MC, Karlsson MO, de Winter W. Weight-HbA1c-Insulin-Glucose model for describing disease progression of type 2 diabetes. CPT Pharm Syst Pharmacol. 2016;5(1):11–19.
   PubMedGoogle Scholar
• Provilus A, Abdallah M, McFarlane SI. Weight gain associated with antidiabetic medications. Therapy. 2011;8(2):113–120.
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). Diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Review Number 173. AHRQ Publication No. 16-EHC013-EF.2016. Available at: https://www.ncbi.nlm.nih.gov/books/NBK362863/. Accessed June 8, 2020..
   Google Scholar
• Gagliardi L, Wittert G. Management of obesity in patients with type 2 diabetes mellitus. Curr Diabetes Rev. 2007;3(2):95–101.
   Google Scholar
• Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab. 2010;12(6):463–473.
   PubMed Web of Science ®Google Scholar
• Lau DCW, Teoh H. Current and emerging pharmacotherapies for weight management in prediabetes and diabetes. Can J Diabetes. 2015;39(5):S134–S141. doi:10.1016/j.jcjd.2015.10.001
   Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–1346. doi:10.1016/S0140-6736(05)61032-X
   PubMed Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi:10.1080/1364557032000119616
   Google Scholar
• Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Flow diagram. Available at: http://prisma-statement.org/documents/PRISMA%202009%20flow%20diagram.pdf. Accessed June 8, 2020.
   Google Scholar
• McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010;12(5):431–436. doi:10.1111/j.1463-1326.2009.01184.x
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, Bellows BK, Unni S, et al. Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). Int J Clin Pract. 2014;68(11):1309–1317. doi:10.1111/ijcp.12502
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, Bellows BK, Unni S, et al. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Spec Pharm. 2014;20(7):691–700.
   Web of Science ®Google Scholar
• Aucott LS, Philip S, Avenell A, Afolabi E, Sattar N, Wild S, on behalf of the Scottish Diabetes Research Network Epidemiology Center. Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study. BMJ Open. 2016;6(7):e010836.
   Web of Science ®Google Scholar
• Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):12. doi:10.1186/s12933-014-0171-2
   PubMed Web of Science ®Google Scholar
• Bron M, Wilson C, Fleck P. A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diabetes Ther. 2014;5(2):521–534.
   PubMed Web of Science ®Google Scholar
• Carter S, Clifton PM, Keogh JB. The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial. Diabetes Res Clin Pract. 2016;122:106–112. doi:10.1016/j.diabres.2016.10.010
   PubMed Web of Science ®Google Scholar
• Chen JF, Chang CM, Kuo MC, Tung SC, Tsao CF, Tsai CJ. Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics. Diabetes Res Clin Pract. 2016;120:8–14.
   Web of Science ®Google Scholar
• Cohen O, Norymberg C, Neumann E, Dekel H. Weight gain in type 2 diabetes mellitus-not all uphill. Diabetes Res Clin Pract. 2008;79(1):128–132. doi:10.1016/j.diabres.2007.07.010
   Web of Science ®Google Scholar
• Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008;10(4):273–277. doi:10.1089/dia.2008.0282
   PubMed Web of Science ®Google Scholar
• Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11(12):1153–1162. doi:10.1111/j.1463-1326.2009.01154.x
   PubMed Web of Science ®Google Scholar
• Del Prato S, Fleck P, Wilson C, Chaudhari P. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(6):623–627.
   Web of Science ®Google Scholar
• Dornhorst A, Lüddeke HJ, Sreenan S, et al, on behalf of the PREDICTIVE Study Group. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE™ study. Int J Clinical Pract. 2008;62(4):659–665. doi:10.1111/j.1742-1241.2008.01715.x
   Web of Science ®Google Scholar
• Duane J, Conway W. Weight management in basal-bolus insulin therapy for type 2 diabetes mellitus: the Deep South Diabetes Program. Insulin. 2008;3(2):95–108. doi:10.1016/S1557-0843(08)80020-6
   Google Scholar
• Feldstein AC, Nichols GA, Smith DH, Rosales AG, Perrin N. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Int Med. 2008;23(9):1339–1345. doi:10.1007/s11606-008-0681-2
   PubMed Web of Science ®Google Scholar
• Feng P, Yu DM, Chen LM, et al, for the Clinical Cooperation Group of Liraglutide in Chinese Type 2 Diabetes. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacol Sin. 2015;36(2):200–208. doi:10.1038/aps.2014.136
   Web of Science ®Google Scholar
• Fonseca V, McDuffie R, Calles J, et al. for the ACCORD Study Group. Determinants of weight gain in the Action to Control Cardiovascular Risk in Diabetes trial. Diabetes Care. 2013;36(8):2162–2168. doi:10.2337/dc12-1391
   Web of Science ®Google Scholar
• Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post hoc analysis. Curr Med Res Opin. 2008;24(3):639–644. doi:10.1185/030079908X260862
   PubMed Web of Science ®Google Scholar
• Harayama T, Yoshida T, Yoshioka K, et al. Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients. Diabetol Int. 2013;4(2):132–137. doi:10.1007/s13340-013-0107-1
   Google Scholar
• Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33(8):1759–1765. doi:10.2337/dc09-2062
   PubMed Web of Science ®Google Scholar
• Huizinga MM, Niswender KD, Gebretsadik T, Rothman RL, Shintani AK, Elasy TA. Insulin use and weight maintenance in well-controlled type 2 diabetes: a prospective cohort study. Obesity. 2008;16(8):1933–1937.
   Web of Science ®Google Scholar
• Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2007;9(3):386–393. doi:10.1111/j.1463-1326.2006.00622.x
   Web of Science ®Google Scholar
• Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361–371. doi:10.1111/j.1463-1326.2008.00970.x
   PubMed Web of Science ®Google Scholar
• Janghorbani M, Amini M, Salehi-Marzijarani M. Weight change, blood pressure, lipids and glycemic control among patients with type 2 diabetes. Ann Nutr Metab. 2011;58(2):141–149. doi:10.1159/000327912
   Web of Science ®Google Scholar
• Jansen HJ, Hendriks JC, De Galan BE, Penders G, Tack CJ, Vervoort G. Contribution of change in glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 diabetic patients. Endocr. 2011;39(2):190–197. doi:10.1007/s12020-010-9423-4
   Web of Science ®Google Scholar
• McAdam-Marx C, Mukherjee J, Bellows BK, et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract. 2014;103(3):402–411. doi:10.1016/j.diabres.2013.12.038
   PubMed Web of Science ®Google Scholar
• Neiberg RH, Wing RR, Bray GA, et al. and the Look AHEAD Research Group. Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD study. Obesity. 2012;20(10):2048–2056. doi:10.1038/oby.2012.33
   Web of Science ®Google Scholar
• Nori Janosz KE, Koenig Berris KA, Leff C, et al. Clinical resolution of type 2 diabetes with reduction in body mass index using meal replacement based weight loss. Vasc Dis Prev. 2008;5(1):17–23. doi:10.2174/1567270000805010003
   Google Scholar
• Umpierrez GE, Pantalone KM, Kwan AYM, Zimmermann AG, Zhang N, Fernández Landó L. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. Diabetes Obes Metab. 2016;18(6):615–622. doi:10.1111/dom.12660
   Web of Science ®Google Scholar
• Watson L, Wilson BP, Alsop J, Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab. 2011;13(9):823–831. doi:10.1111/j.1463-1326.2011.01413.x
   PubMed Web of Science ®Google Scholar
• Wing RR, Lang W, Wadden TA, et al. for the Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486. doi:10.2337/dc10-2415
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhao X, Chen M, Fang Z, Chen Y, Wang Y. Weight gain and changes in plasma adiponectin and leptin concentrations after 12-month insulin intensive therapy for Chinese male patients with newly diagnosed type 2 diabetes. Obes Res Clin Pract. 2016;10(5):553–563. doi:10.1016/j.orcp.2015.09.005
   Web of Science ®Google Scholar
• Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14(1):77–82.
   PubMed Web of Science ®Google Scholar
• Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle Weight-Loss Intervention Outcomes in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Acad Nutr Diet. 2015;115(9):1447–1463. doi:10.1016/j.jand.2015.02.031
   PubMed Web of Science ®Google Scholar
• Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1295–1305. doi:10.1111/dom.12971
   PubMed Web of Science ®Google Scholar
• Nichols GA, Bell K, Kimes TM, O’Keeffe-Rosetti M. Medical care costs associated with long-term weight maintenance versus weight gain among patients with type 2 diabetes. Diabetes Care. 2016;39:1981–1986.
   Web of Science ®Google Scholar
• Davis WA, Bruce DG, Davis TME. Economic impact of moderate weight loss in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabet Med. 2011;28(9):1131–1135.
   Web of Science ®Google Scholar
• Mohamed AF, Zhang J, Johnson FR, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39:397–403.
   PubMedGoogle Scholar
• Mukherjee J, Sternhufvud C, Smith N, et al. Association between weight change, clinical outcomes, and health care costs in patients with type 2 diabetes. J Manag Care Spec Pharm. 2016;22(5):449–466.
   Google Scholar
• Bell K, Parasuraman S, Shah M, et al. Economic implications of weight change in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20:e320–e329.
   PubMed Web of Science ®Google Scholar
• Blak BT, Rigney U, Sternhufvud C, Davis J, Hammar N. Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class. Int J Clin Pract. 2016;70(1):45–55.
   Web of Science ®Google Scholar
• Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin. 2007;23:2157–2169.
   PubMed Web of Science ®Google Scholar
• Meads DM, Hulme CT, Hall P, Hill AJ. The cost-effectiveness of primary care referral to a UK commercial weight loss programme. Clin Obes. 2014;4(6):324–332.
   Google Scholar
• Thorpe KE, Yang Z, Long KM, Garvey WT. The impact of weight loss among seniors on Medicare spending. Health Econ Rev. 2013;3(1):1–6.
   Google Scholar
• Trueman P, Haynes SM, Felicity Lyons G, et al. Long-term cost-effectiveness of weight management in primary care. Int J Clin Pract. 2010;64(6):775–783.
   Web of Science ®Google Scholar
• Sabale U, Bodegard J, Svennblad B, et al. Weight change patterns and healthcare costs in patients with newly-diagnosed type-2 diabetes in Sweden. Prim Care Diabetes. 2017;11(3):217–225.
   Web of Science ®Google Scholar
• Duong JK, de Winter W, Choy S, et al. The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model. Br J Clin Pharmacol. 2017;83(3):487–497.
   Web of Science ®Google Scholar
• Pappachan JM, Viswanath AK. Medical management of diabesity: do we have realistic targets? Curr Diab Rep. 2017;17(1):4.
   Web of Science ®Google Scholar
• DerSarkissian M, Bhak RH, Huang J, et al. Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population. Curr Med Res Opin. 2017;33(6):1105–1110.
   PubMed Web of Science ®Google Scholar
• Karkare S, Fridman M, Dang-Tan T, et al. Effect of weight change on economic outcomes among persons with type 2 diabetes mellitus in the United States: beyond glycemic control. J Manag Care Spec Pharm. 2019;25(6):658–668.
   PubMed Web of Science ®Google Scholar
• Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81–87.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Camastra S, Gastaldelli A, et al. β-cell function in obesity. Diabetes. 2004;53(Suppl3):S26–S33.
   Web of Science ®Google Scholar